Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05438329 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by DualityBio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 1,123
- Enrollment target
- 20
- Study locations
NCT05438329 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by DualityBio. The registered enrollment target is 1,123 participants, above the 187-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (501% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT05438329, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by DualityBio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 1,123 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors.
Conditions Studied
Interventions
- DRUG DB-1305/BNT325
- COMBINATION_PRODUCT Pembrolizumab
- DRUG BNT327
Study Locations (20)
Florida
- D&H Cancer Research Center Llc - Margate
- Site 109 - Plantation
- BRCR Medical Center Inc. - Tamarac
California
- Site 103 - Cerritos
- Site 108 - Los Angeles
Texas
- Site 110 - Arlington
- Site 104 - Houston
Anhui
- Site 211 - Bengbu
- Site 217 - Hefei
Michigan
- Site 106 - Detroit
New York
- Site 102 - New York
Ohio
- Site 101 - Canton
Tennessee
- Site 105 - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,123 participants |
| Start Date | 2022-07-19 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05438329
The ClinicalTrials.gov registry entry for NCT05438329 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 1,123 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 187-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (501% higher). The listed sponsor is DualityBio, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which DB-1305/BNT325 is the first listed.
NCT05438329 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, California, Texas.
Frequently Asked Questions
What is clinical trial NCT05438329 about?
NCT05438329 is a clinical study titled "First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors". This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors.
What is the current status of trial NCT05438329?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 1,123 participants. The study started on 2022-07-19. Estimated completion is 2025-06-30.
What conditions does trial NCT05438329 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT05438329?
The interventions under investigation include: DB-1305/BNT325 (DRUG), Pembrolizumab (COMBINATION_PRODUCT), BNT327 (DRUG).
Who is sponsoring clinical trial NCT05438329?
This trial is sponsored by DualityBio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05438329 being conducted?
This trial has 20 study locations across California, Florida, Michigan, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.